Adolfo Favaretto researcher
Favaretto, Adolfo
VIAF ID: 6784155566443313380006 (Personal)
Permalink: http://viaf.org/viaf/6784155566443313380006
Preferred Forms
- 100 0 _ ‡a Adolfo Favaretto ‡c researcher
- 100 1 _ ‡a Favaretto, Adolfo
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
Bone marrow myeloid cell kinetics during treatment of small cell carcinoma of the lung with chemotherapy not associated and associated with granulocyte-macrophage colony-stimulating factor | |
Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesothelioma. | |
Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm | |
Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. | |
Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment | |
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. | |
EAGLES study: First-line Bevacizumab in Combination with Chemotherapy in Elderly Patients with Advanced, Metastatic, Non-squamous Non-small Cell Lung Cancer. | |
Effects of sulfonylureas on tumor growth: a review of the literature | |
HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer. | |
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results | |
Long-term survival and prognostic factors in thymic epithelial tumours | |
MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data | |
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer. | |
Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman. | |
Multidisciplinary approach for advanced stage thymic tumors: long-term outcome | |
Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer. | |
Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens | |
Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection. | |
Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study. | |
Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. | |
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients. | |
Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer. | |
Pre-operative chemoradiotherapy in non-small cell lung cancer stage III patients. Feasibility, toxicity and long-term results of a phase II study. | |
The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy | |
Preoperative concomitant chemo-radiotherapy in superior sulcus tumour: A mono-institutional experience. | |
Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey | |
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. | |
Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. | |
Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. | |
Results of surgical resection after induction chemoradiation for Pancoast tumours †. | |
Second and third responses to the same induction regimen in relapsing patients with multiple myeloma | |
A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors | |
Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization | |
Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease | |
The surgeon and the oncologist in non-small cell lung cancer (NSCLC). | |
Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. | |
Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma | |
Treatment of Unfit Patients With Advanced Non-Small-Cell Lung Cancer: Definition Criteria According an Expert Panel. | |
Ultrarapid high-dose course of prophylactic cranial irradiation in small-cell lung cancer: evaluation of late neurologic morbidity in 16 long-term survivors. |